Cathie Wood, the CEO of ARK Investment Management, is known for her investments in disruptive technologies. The information technology, healthcare, financial services, consumer discretionary, and telecommunications sectors are among the holdings of Wood’s hedge fund. The company’s clients include digital commerce and genomics companies. Q4 2021 regulatory filings show that ARK Investment Management has a 13F portfolio worth $33 billion, down from $41.6 billion in the previous quarter. In comparison to the S&P 500’s 9% decline, the ARK Innovation ETF fell 30% in 2018.
Insider Monkey selected 10 innovative stocks from Cathie Wood’s Q4 portfolio that failed to impress. An American biotechnology company, Pacific Biosciences of California, Inc., uses single-molecule real time gene sequencing. Cathie Wood increased her stake in the company by 17 percent in Q4 2021, despite the company’s poor performance. Financial services company Robinhood Markets, Inc. provides a mobile application for users to trade stocks, ETFs and cryptocurrencies. There are 23.8 million shares worth $423.5 million owned by Cathie Wood’s ARK Investment Management. Ark Investment Management holds CRISPR Therapeutics AG as one of its innovative stocks. Gene editing is used to develop pharmaceuticals by the company. As of today, RBC Capital analyst Lucia Isi has downgraded RBC Capital’s price target for the stock from $117 to $95. Cathie Wood increased her stake in StoneCo Ltd. by 53% in Q4 2021, despite the company’s recent underperformance. Increasing interest rates in Brazil are to blame for the lower forecasts and target price set by the analyst. Incorporated in California, Roku, Inc. designs and manufactures a variety of streaming media devices. However, the company’s “broadly positive” Q4 results were overshadowed by weaker forecasts for Q1 and fiscal 2022. For more details, click 10 Innovative Stocks In Cathie Wood’s Portfolio That Failed To Impress.